Stockscreener 앱 받기
4.19
1.95%
0.08
전일 마감가:
$4.11
열려 있는:
$4.15
하루 거래량:
761.04K
Relative Volume:
0.61
시가총액:
$179.33M
수익:
$1.23M
순이익/손실:
$-28.62M
주가수익비율:
-2.6691
EPS:
-1.5698
순현금흐름:
$-14.11M
1주 성능:
+8.27%
1개월 성능:
+11.44%
6개월 성능:
+88.74%
1년 성능:
+28.13%
1일 변동 폭
$4.04
$4.255
1주일 범위
$3.80
$4.255
52주 변동 폭
$1.62
$5.055
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
명칭
Nrx Pharmaceuticals Inc
전화
484-254-6134
주소
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
4.19 | 179.33M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-08 | 개시 | H.C. Wainwright | Buy |
| 2025-04-02 | 개시 | BTIG Research | Buy |
Nrx Pharmaceuticals Inc 주식(NRXP)의 최신 뉴스
Equity in earnings of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
NRXP Should I Buy - Intellectia AI
First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell 3000E Growth Benchmark - marketscreener.com
NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Price to book forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to sales forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to sales forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Enterprise value to EBITDA forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Price to earnings forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to EBIT forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to EBIT forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to earnings forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
NRX Pharmaceuticals(NRXP) Stock Options Chain | Quotes & News - Moomoo
H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP) - The Globe and Mail
NRx Pharmaceuticals Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
NRX Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:NRXP) - TradingView
NRx Pharmaceuticals responds to Kadima dispute claims - Investing.com UK
NRx Pharmaceuticals responds to Kadima dispute claims By Investing.com - Investing.com South Africa
NRXP Stock Price, Quote & Chart - ChartMill
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute - GlobeNewswire
NRx subsidiary begins AI-guided TMS treatments in Florida - Investing.com UK
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE - GlobeNewswire
Kadima sues NRx Pharmaceuticals over failed acquisition deal - Investing.com UK
Kadima Neuropsychiatry Institute Sues NRX Pharmaceuticals Over Breach of Acquisition Contract - marketscreener.com
Kadima sues NRx Pharmaceuticals over failed acquisition deal By Investing.com - Investing.com South Africa
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition - Business Wire
NRx Pharmaceuticals, Inc. (NRXP) reports Q1 loss, lags revenue estimates - MSN
ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics - Sahm
BTIG Maintains NRX Pharmaceuticals(NRXP.US) With Buy Rating, Maintains Target Price $25 - Moomoo
EBIT per share of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Cash per share of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Tangible book value per share of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Total common shares outstanding of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Operating income of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Net income before discontinued operations of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
NRX Pharmaceuticals, Inc. Income Statement – DUS:B1Q - TradingView
NRX Pharmaceuticals, Inc. Balance Sheet – DUS:B1Q - TradingView
NRX Pharmaceuticals' Hope Therapeutics, Zeta Surgical Treat First Patient With Zeta TMS Navigation System - marketscreener.com
NRx-backed clinic begins guided brain therapy at two Florida sites - Stock Titan
NRX Pharmaceuticals Inc (NRXPW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression - Investing News Network
NRx Pharmaceuticals gets FDA approval for NRX-101 protocol - grafa.com
NRx Pharmaceuticals Receives Expanded Access Approval for Experimental Depression Treatment - marketscreener.com
FDA lets NRx offer NRX-101 with TMS for severe depression - Stock Titan
NRX Pharmaceuticals Inc (NRXPW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NRX Pharmaceuticals Inc (NRXPW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nrx Pharmaceuticals Inc (NRXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):